Additional file 2: of Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study
- Motomu Hashimoto (388292)
- Moritoshi Furu (105348)
- Wararu Yamamoto (5594390)
- Takanori Fujimura (4966762)
- Ryota Hara (4966744)
- Masaki Katayama (152645)
- Akira Ohnishi (4966750)
- Kengo Akashi (3486011)
- Shuzo Yoshida (525805)
- Koji Nagai (4966753)
- Yonsu Son (4966759)
- Hideki Amuro (4966747)
- Toru Hirano (2738686)
- Kosuke Ebina (326525)
- Ryuji Uozumi (5594393)
- Hiromu Ito (164599)
- Masao Tanaka (107633)
- Koichiro Ohmura (137137)
- Takao Fujii (199007)
- Tsuneyo Mimori (114039)
Publication date
August 2018
DOIAbstract
Figure S2. Kaplan–Meier survival curve for maintaining bDMARD-free remission after discontinuation of different types of bDMARDs in bDMARD-naïve patients. bDMARD-naïve patients classified into four groups based on types of bDMARDs. Kaplan–Meier method used to estimate BFR maintenance time. bDMARD biological disease-modifying anti-rheumatic drug, BFR biological disease-modifying anti-rheumatic drug-free remission, TNFi(mAb) monoclonal antibodies against TNF (infliximab, adalimumab, and golimumab), TNFi(R/P) soluble TNF receptor or Fab fragments against TNF fused with polyethylene glycol (etanercept and certolizumab), CTLA4-Ig abatacept, IL-6Ri interleukin-6 receptor inhibitor (tocilizumab), CI confidence interval (PDF 80 kb) (PDF 79 kb
Add to ORKG